THYROLAR-0.25
LOE ApproachingNDAORALTABLET
Approved
Nov 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THYROLAR-0.25 is an oral tablet containing a combination of thyroid hormones (levothyroxine and liothyronine) approved in 1969 for treatment of hypothyroidism and thyroid cancer. The product works by replacing deficient thyroid hormone to restore normal metabolic function. It is a legacy oral formulation in the endocrinology space.
LOE Approaching
Mature product nearing loss of exclusivity with moderate competitive pressure (30%) suggests a lean, maintenance-focused commercial team focused on retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
THYROLAR-0.25 offers limited career growth opportunity with zero linked job openings and an approaching LOE phase. Roles on this product focus on defensive commercial strategies rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on THYROLAR-0.25 at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.